Adicet Bio, Inc. (ACET) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 9 Buy, 3 Hold.
The consensus price target is $18.00, representing an upside of 157.1% from the current price $7.00.
Analysts estimate Earnings Per Share (EPS) of $-25.44 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.33 vs est $-25.44 (beat +94.8%). 2025: actual $-16.95 vs est $-16.17 (missed -4.8%). Analyst accuracy: 0%.
ACET Stock — 12-Month Price Forecast
$18.00
▲ +157.14% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for Adicet Bio, Inc., the price target is $18.00.
The average price target represents a +157.14% change from the last price of $7.00.
ACET Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to Adicet Bio, Inc. in the past 3 months
EPS Estimates — ACET
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.33
vs Est –$25.44
▲ 1,812.8% off
2025
Actual –$16.95
vs Est –$16.17
▼ 4.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — ACET
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
